 Shares of Voyager Therapeutics Inc. VYGR rallied 35 in premarket trading on Monday after the company announced a deal with Neurocrine Biosciences Inc. NBIX to develop and commercialize gene therapies, including one that is being tested as a treatment for Parkinsons disease. Neurocrine will make a 175 million upfront payment, including a 39 million equity ... The post : Voyager, Neurocrine ink gene-therapy deal appeared first on ForexTV... 